Insider Selling: Beta Bionics (NASDAQ:BBNX) CFO Sells $12,648.00 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) CFO Stephen Feider sold 744 shares of Beta Bionics stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $17.00, for a total transaction of $12,648.00. Following the sale, the chief financial officer owned 159,378 shares of the company’s stock, valued at approximately $2,709,426. This represents a 0.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Stephen Feider also recently made the following trade(s):

  • On Thursday, November 5th, Stephen Feider sold 382 shares of Beta Bionics stock. The stock was sold at an average price of $17.04, for a total transaction of $6,509.28.
  • On Wednesday, September 2nd, Stephen Feider sold 6,675 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total transaction of $127,559.25.

Beta Bionics Stock Down 0.5%

NASDAQ BBNX traded down $0.09 during trading hours on Friday, hitting $16.42. The company’s stock had a trading volume of 1,095,375 shares, compared to its average volume of 1,171,084. The stock has a fifty day moving average of $18.47 and a 200 day moving average of $14.86. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71. The firm has a market capitalization of $892.76 million, a P/E ratio of -8.92 and a beta of 3.44.

Beta Bionics (NASDAQ:BBNX – Get Free Report) last released its earnings results on Tuesday, October 27th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.01. The firm had revenue of $35.51 million during the quarter. Beta Bionics had a negative net margin of 65.31% and a negative return on equity of 27.33%. On average, analysts predict that Beta Bionics, Inc. will post -2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

BBNX has been the subject of a number of analyst reports. Barclays began coverage on Beta Bionics in a research note on Tuesday, October 6th. They set an “overweight” rating and a $30.00 price objective for the company. Wall Street Zen downgraded Beta Bionics from a “hold” rating to a “strong sell” rating in a report on Saturday, October 31st. Robert W. Baird increased their target price on Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Tuesday, September 15th. Weiss Ratings upgraded Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Finally, William Blair initiated coverage on Beta Bionics in a report on Friday, August 21st. They set a “market perform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Beta Bionics currently has an average rating of “Moderate Buy” and an average price target of $23.69.

View Our Latest Stock Analysis on Beta Bionics

Institutional Investors Weigh In On Beta Bionics

Several hedge funds have recently bought and sold shares of the company. Legal & General Group Plc bought a new position in shares of Beta Bionics during the second quarter worth $62,000. The Manufacturers Life Insurance Company bought a new stake in shares of Beta Bionics in the 2nd quarter valued at $172,000. 49 Wealth Management LLC bought a new stake in shares of Beta Bionics in the 3rd quarter valued at $260,000. Ieq Capital LLC bought a new stake in shares of Beta Bionics in the 2nd quarter valued at $229,000. Finally, Quantbot Technologies LP acquired a new stake in Beta Bionics during the 2nd quarter worth $264,000.

About Beta Bionics

(Get Free Report)

Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings.

Recommended Stories

Insider Buying and Selling by Quarter for Beta Bionics (NASDAQ:BBNX)

Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.